Purizumubaiorabo
206A.TTSE GROWTHPharmaceutical
Filed as PRISM BioLab Co.,LTD (2024-12–2026-05)
Financials · Standalone
| Fiscal year ended | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 | 2020-09 |
|---|---|---|---|---|---|---|
| Revenue | ¥677m | ¥306m | ¥113m | ¥554m | ¥59m | ¥206m |
| Operating income | −¥774m | −¥782m | −¥497m | — | — | — |
| Ordinary income | −¥748m | −¥832m | −¥498m | ¥79m | −¥154m | −¥140m |
| Total assets | ¥3.1bn | ¥4.5bn | ¥1.2bn | ¥1.7bn | ¥1.5bn | ¥401m |
| Net assets / equity | ¥2.7bn | ¥3.5bn | ¥1.1bn | ¥1.7bn | ¥1.1bn | −¥51m |
| Operating cash flow | −¥1.5bn | ¥150m | −¥514m | ¥103m | — | — |
| EPS (basic) | ¥-22.82 | ¥-33.53 | ¥-19.09 | ¥2.67 | ¥-1,556.87 | ¥-1,469.95 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2023-10-01 → 2024-09-30 | Annual | 97 figures · EDINET |